Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fowlpox Vaccine With or Without IL-2 in Metastatic Melanoma
NCT00019669Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 1999
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp100-fowlpox vaccine in melanoma (4 cohorts), sponsored by National Cancer Institute. Primary endpoints: Clinical Response, Immune Response and 1 more. Started Oct 1999; status: completed.
02
Drugs
gp100-fowlpox vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019669.